PROTOCOL WRITING SERVICES
BioBoston CRO supports clinical trial protocol writing when a sponsor needs to turn an approved study concept, protocol synopsis, objectives, endpoints, and cross-functional inputs into a complete, controlled, reviewable protocol document.
The service may begin with an approved synopsis, an incomplete draft, a protocol that requires substantial restructuring, or a planned amendment. Product Development Planning owns the earlier development roadmap, protocol concept, synopsis, endpoint-strategy, and CRO-selection work. Protocol Writing owns full authoring and development of the complete protocol document.
The sponsor and designated medical, statistical, regulatory, operational, safety, data, and quality owners remain responsible for their decisions and approvals. The writer organizes those inputs, identifies gaps, develops the document, supports consolidated review, and prepares the agreed finalization package.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
The study objectives, endpoints, population, intervention, and core design are substantially defined, but the full document has not been authored.
A protocol exists, but sections are incomplete, inconsistent, difficult to review, or no longer aligned with current study decisions.
Medical, statistical, regulatory, operations, safety, data, and vendor contributors need one controlled authoring and review process.
The sponsor needs to update the protocol and associated content while preserving rationale, consistency, traceability, and version control.
COMMON TIMING
Protocol writing support is most effective when the study concept is sufficiently mature to support authoring and when the review team can make the decisions required to close open items.
PROBLEMS ADDRESSED
Objectives, endpoints, estimands where applicable, assessments, and analyses do not form a coherent chain from the study question to the planned evidence.
Inclusion and exclusion criteria conflict with the target population, operational feasibility, safety monitoring, or related protocol sections.
Visits, procedures, sampling, safety assessments, windows, and footnotes differ between the table and the narrative.
Medical, statistics, data, operations, safety, regulatory, and vendors are revising different sections without one controlled document owner.
Open decisions are embedded in prose, comments, or local files instead of being tracked, assigned, and resolved.
Sites, monitors, data teams, vendors, and reviewers could interpret procedures, timing, responsibilities, or escalation differently.
FOCUSED SERVICE SCOPE
The exact scope depends on the maturity of the study concept and source package. A protocol-writing
engagement may include the following activities without transferring sponsor decision authority.
LIKELY OUTPUTS
SPONSOR READINESS
The sponsor does not need every detail finalized before kickoff, but the engagement must distinguish approved decisions from open questions and identify who can resolve each question.
A controlled protocol writing and review process
1. Kick off the engagement and confirm protocol purpose, maturity, intended use, stakeholders, responsibilities, milestone, and review model.
2. Review the synopsis, source package, current draft, templates, and related documents; issue a gap and open item list.
3. Create the protocol outline, source map, authoring plan, responsibility matrix, and decision tracker.
4. Draft the protocol in controlled sections while coordinating approved medical, statistical, regulatory, operational, safety, data, and vendor input.
5. Run a consolidated cross-functional review, separate required decisions from preferences, and resolve comments through designated owners.
6. Perform the agreed quality-control checks, prepare clean and redline versions, and support sponsor approval or downstream handoff.
REVIEW DISCIPLINE
A well-written protocol is not simply complete prose. The document must communicate the approved study logic consistently enough that reviewers, vendors, sites, data teams, safety teams, and future report authors can apply it as intended.
WAYS TO ENGAGE
Develop the complete protocol using the approved study concept and a defined cross-functional source package.
Assess and substantially rewrite a stalled, fragmented, or heavily commented protocol while preserving approved decisions.
Author or strengthen defined protocol sections when ownership and interfaces with the full document are clear.
Integrate approved changes across affected sections, schedules, tables, definitions, rationales, and related content as scoped.
Review a sponsor- or vendor-authored protocol for clarity, consistency, completeness, operational interpretation, and defined quality criteria.
CONNECTED SUPPORT
Use this service for the clinical development plan, early study concept, protocol synopsis, endpoint strategy, CRO selection, and early trial budget review.
Engage biostatistics for statistical strategy, sample size, analysis planning, randomization, outputs, and programming decisions that inform the protocol.
Return to the parent pillar for related writing needs such as Investigator Brochures, Clinical Study Reports, briefing books, submission documents, and document quality control.
Use Regulatory Affairs for pathway, meeting strategy, submission planning, regulatory positioning, and questions that shape the protocol’s regulatory context.
Use operational strategy, feasibility, vendor evaluation, sponsor-side oversight, or partner-supported coordination to test whether protocol procedures can be implemented as intended.
Coordinate protocol dependencies, contributor responsibilities, review windows, decision logs, milestones, and downstream handoffs.
WRITER FIT
Protocol writing requires more than general editorial skill. The selected writer should understand the document type, study stage, product or technology, cross-functional inputs, intended review environment, and operational implications. Additional medical, statistical, regulatory, safety, data, or quality review should be assigned when the protocol requires it.
PLANNED GUIDANCE
A planned educational article covering protocol sections, source readiness, review ownership, common risks, and sponsor decisions.
A planned comparison resource that explains when early concept work belongs to Product Development Planning and when full authoring belongs to Protocol Writing.
A planned practical checklist for objectives, endpoints, eligibility, schedule of activities, safety, statistics, data, operations, consistency, and open items.
QUESTIONS SPONSORS ASK
A scoped engagement may include source review, gap identification, outline and authoring planning, complete protocol drafting or substantial rewriting, cross-functional input integration, consolidated review support, comment resolution, quality control, clean and redline versions, and finalization support. The exact work depends on the maturity of the concept and draft.
A mature synopsis is the most efficient starting point, but the protocol may begin while a limited number of decisions remain open if owners and resolution dates are clear. When the study concept, endpoints, or development path are still materially uncertain, Product Development Planning should lead or run in parallel.
This page may discuss design only in the context of translating approved design decisions into the complete protocol and identifying inconsistencies or gaps. Early study design, development planning, protocol synopsis, and endpoint strategy belong to Product Development Planning, with Biostatistics supporting statistical design decisions.
Yes. The engagement can begin with an existing draft and comment history. BioBoston should first assess the document condition, approved decisions, unresolved items, source package, review ownership, and remaining milestone before confirming the rescue scope.
The review team depends on the study, but commonly includes designated medical or clinical leadership, biostatistics, clinical operations, regulatory affairs, safety, data management, quality, and relevant product or vendor specialists. The sponsor should identify decision owners and use a consolidated review process.
Timing depends on concept maturity, source readiness, protocol complexity, reviewer availability, decision latency, amendment history, and the number of agreed review cycles. A schedule should be proposed only after the current materials and review model are assessed.
No. Clear protocol writing and disciplined review can reduce avoidable ambiguity and inconsistency, but BioBoston should not promise regulatory acceptance, enrollment, execution success, or freedom from amendments. The sponsor retains decision and approval responsibility.
START A CONVERSATION
Share the study phase or type, current protocol stage, target milestone, and the writing support you need. A BioBoston team member will review your request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
